Page 13 - PRESENTATION
P. 13

Probability of Prostate Cancer Recurrence after RP















                                        Preoperative nomogram                                                                                    Charles has only a 30% probability of being

                                                                                                                                                          progression-free at 10 years after RP






                                                Calculated Progression-Free Probability






                             120               98% 97% 95%            90%        80% 70%     60% 40% 20%          10%   5% 1%                            Preoperative PSA
                                                                                                 50% 30%
                                       99%                                                                                                                                                0      1      2      3      4      5    6     7        10        20     30    40 50
                             108
                                                                                                                                                         No. Positive Cores
                          Months from Surgery
                               96                                                                                                                                                         0   3   5    7   9 11     14

                               84                                                                                                                        No. Negative Cores

                                                                                                                                                                                         20   18    16   14   12 10      8     6    4    2    0
                               72
                                                                                                                                                                                           T1C                  T2B
                               60                                                                                                                        Clinical Stage

                                                                                                                                                                                        T2A         T2C                 T3
                               48                                                                                                                                                                                                          ≥ 4

                                                                                                                                                                      o
                                                                                                                                                         Biopsy 1 Gleason
                               36                                                                                                                                                        ≤ 3                                                         ≥ 4

                                                                                                                                                                      o
                                                                                                                                                         Biopsy 2 Gleason
                                                                                                                                                                                                                           ≤ 3
                               12
                                                                                                                                                         Points

                                  0             50           100            150            200            250           300            350                                                0       10       20      30      40       50      60       70      80       90      100












        14 Stephenson AJ et al. J Natl Cancer Inst 2006;98:715-717.
   8   9   10   11   12   13   14   15   16   17   18